Forty-one of the 285 study patients were identified as FH based on detected pathogenic/likely pathogenic variants on their LDLR, APOB, or PCSK9 gene, which equated to a prevalence as high as 14.4%. This evidence concerns the gene LDLR and familial hyperaldosteronism.